Homepage

Zoetis Inc.

ZTS NYSE Categories PDF
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Updated May 11, 1:54pm
$77.51
Price
$32.5B
Market Cap
13,800
Employees
0.86
Beta
Kristin C. Peck
CEO
Business Description

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Business History
Price Overview
Last updated: May 11, 2026 1:54pm (just now)
$77.51
-5.32 (-6.42%)
Day Range
$76.53 – $82.12
52-Week Range
$76.54 – $172.23
50-Day MA
$117.14
200-Day MA
$130.98
Volume
9,298,074.00
Analyst Price Targets
Low $99.00
Consensus $133.57
High $160.00
(24 analysts)
Share Structure
Outstanding 419,228,146.00
Float 418,402,239.00
Free Float 99.8%
High free float — 99.8% of shares trade freely, ~0.2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
API
Stock Price / EPS (Diluted)
12.38
Stock Price: $77.51
EPS (Diluted): 6.03
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
16.75
Stock Price: $77.51
Total Equity: $3.33B
Shares: 443,835,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
7.61
Market Cap: $32.49B
Total Debt: $9.29B
Cash: $2.31B
EBITDA: $4.07B
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$63.0B
Market Cap: $32.49B
Total Debt: $9.29B
Cash: $2.31B
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
70.5%
Gross Profit: $6.67B
Revenue: $9.47B
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
38.0%
Operating Income: $3.60B
Revenue: $9.47B
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
28.2%
Net Income: $2.67B
Revenue: $9.47B
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
62.4%
Net Income: $2.67B
Total Equity: $3.33B
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
21.8%
Operating Income: $3.60B
Tax Rate: 20.4%
Equity: $3.33B
Total Debt: $9.29B
Cash: $2.31B
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
3.03
Current Assets: $6.77B
Current Liabilities: $2.24B
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
2.79
Short-Term Debt: $53.00M
Long-Term Debt: $9.24B
Total Debt: $9.29B
Total Equity: $3.33B
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$21.33
Revenue: $9.47B
Shares: 443,835,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$7.51
Total Equity: $3.33B
Shares: 443,835,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$5.14
Operating CF: $2.90B
CapEx: -$621.00M
Shares: 443,835,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
1.6%
Last Dividend: N/A
Stock Price: $77.51
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $2.67B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ZTS against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $7.8B $8.1B $8.5B $9.3B $9.5B
Cost of Revenue $2.5B $2.6B $2.7B $2.9B $2.8B
Gross Profit $5.3B $5.5B $5.8B $6.4B $6.7B
Operating Expenses $2.5B $2.5B $2.8B $3.0B $3.1B
Operating Income $2.8B $2.9B $3.1B $3.4B $3.6B
Net Income $2.0B $2.1B $2.3B $2.5B $2.7B
EBITDA $3.2B $3.4B $3.7B $3.9B $4.1B
EPS $4.29 $4.51 $5.08 $5.47 $6.03
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $3.5B $3.6B $2.0B $2.0B $2.3B
Total Current Assets $6.9B $7.5B $6.3B $6.0B $6.8B
Total Assets $13.9B $14.9B $14.3B $14.2B $15.5B
Current Liabilities $1.8B $3.2B $1.9B $3.4B $2.2B
Long-Term Debt $6.6B $6.6B $6.6B $5.2B $9.2B
Total Liabilities $9.4B $10.5B $9.3B $9.5B $12.1B
Total Equity $4.5B $4.4B $5.0B $4.8B $3.3B
Retained Earnings $7.2B $8.7B $10.3B $12.0B $13.7B
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $2.2B $1.9B $2.4B $3.0B $2.9B
Capital Expenditure -$477.0M -$586.0M -$732.0M -$655.0M -$621.0M
Free Cash Flow $1.7B $1.3B $1.6B $2.3B $2.3B
Acquisitions (net) -$14.0M -$312.0M -$59.0M $285.0M -$24.0M
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks -$743.0M -$1.6B -$1.1B -$1.9B -$3.2B
Net Change in Cash -$119.0M $96.0M -$1.5B -$54.0M $325.0M
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $10.3B
$10.1B – $10.5B
 $10.8B
$10.7B – $10.8B
 $11.2B
$11.0B – $11.5B
 $11.7B
$11.5B – $12.0B
EBITDA $4.6B
$4.5B – $4.7B
 $4.9B
$4.8B – $4.9B
 $5.1B
$5.0B – $5.2B
 $5.3B
$5.2B – $5.4B
Net Income $3.3B
$3.2B – $3.4B
 $3.6B
$3.5B – $3.8B
 $3.9B
$3.8B – $4.0B
 $4.2B
$4.1B – $4.3B
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth +3.9% +5.7% +8.3% +2.3%
Gross Profit Growth +3.1% +6.5% +9.6% +4.3%
Operating Income Growth +4.5% +4.8% +10.5% +6.0%
Net Income Growth +3.8% +10.9% +6.1% +7.5%
EBITDA Growth +5.9% +9.7% +5.1% +5.1%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-04-30 Esch Kevin M-Exempt 259.00 $0.00 $0
2026-04-30 Esch Kevin F-InKind 75.00 $114.97 $8,623
2026-04-30 Esch Kevin M-Exempt 259.92 $0.00 $0
2026-04-10 FULLER JULIE A-Award 550.64 $0.00 $0
2026-04-10 Lagano Roxanne A-Award 550.64 $0.00 $0
2026-04-10 Ferran Astorga Jeannette A-Award 5.00 $0.00 $0
2026-04-10 Esch Kevin A-Award 1.39 $0.00 $0
2026-04-10 PECK KRISTIN C A-Award 2,776.77 $0.00 $0
2026-04-10 Driscoll Rimma A-Award 26.20 $0.00 $0
2026-04-10 Joseph Wetteny A-Award 873.95 $0.00 $0
2026-04-10 Sarbaugh Keith A-Award 230.76 $0.00 $0
2026-03-31 Sarbaugh Keith M-Exempt 1,528.00 $0.00 $0
2026-03-31 Sarbaugh Keith F-InKind 524.00 $118.21 $61,942
2026-03-31 Sarbaugh Keith M-Exempt 1,528.02 $0.00 $0
2026-03-27 FULLER JULIE A-Award 669.34 $0.00 $0
2026-03-27 Joseph Wetteny A-Award 2,114.76 $0.00 $0
2026-03-27 PECK KRISTIN C A-Award 4,391.26 $0.00 $0
2026-03-27 Driscoll Rimma A-Award 641.74 $0.00 $0
2026-03-27 Esch Kevin A-Award 219.95 $0.00 $0
2026-03-27 Ferran Astorga Jeannette A-Award 593.17 $0.00 $0
Dividend History (Last 20)
Date Dividend Declaration Record Payment
2026-04-20 $0.53 2026-02-05 2026-04-20 2026-06-02
2026-01-20 $0.53 2025-12-11 2026-01-20 2026-03-03
2025-10-31 $0.50 2025-10-09 2025-10-31 2025-12-02
2025-07-18 $0.50 2025-05-21 2025-07-18 2025-09-03
2025-04-21 $0.50 2025-02-06 2025-04-21 2025-06-03
2025-01-21 $0.50 2024-12-12 2025-01-21 2025-03-04
2024-10-31 $0.43 2024-10-10 2024-10-31 2024-12-03
2024-07-18 $0.43 2024-05-22 2024-07-18 2024-09-04
2024-04-18 $0.43 2024-02-06 2024-04-19 2024-06-04
2024-01-18 $0.43 2023-12-07 2024-01-19 2024-03-01
2023-10-31 $0.38 2023-10-12 2023-11-01 2023-12-01
2023-07-20 $0.38 2023-05-11 2023-07-21 2023-09-01
2023-04-20 $0.38 2023-02-08 2023-04-21 2023-06-01
2023-01-19 $0.38 2022-12-08 2023-01-20 2023-03-01
2022-10-31 $0.33 2022-10-13 2022-11-01 2022-12-01
2022-07-20 $0.33 2022-05-19 2022-07-21 2022-09-01
2022-04-20 $0.33 2022-02-08 2022-04-21 2022-06-01
2022-01-19 $0.33 2021-12-07 2022-01-20 2022-03-01
2021-10-28 $0.25 2021-10-14 2021-10-29 2021-12-01
2021-07-20 $0.25 2021-05-20 2021-07-21 2021-09-01
Community AI Feedback
Sign in to Contribute
No community reviews yet for ZTS. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27